HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Limited Brands Canada

This article was originally published in The Rose Sheet

Executive Summary

Columbus, Ohio-based company is creating Limited Brands Canada, a Montreal-based division that will support all Limited Brands retail stores and strategic expansion in Canada for brands including Bath & Body Works, Victoria's Secret and lingerie brand La Senza, the firm announces April 14. "We believe a Canadian-based team dedicated to the execution of our brands will provide a foundation for effectively leveraging talent and resources across key operating disciplines," Martin Waters, president of Limited Brands international division, says in the release. Joanne Nemeroff, currently president of La Senza, has been named president of Limited Brands Canada. Limited Brands established a platform for Canadian retail expansion with its purchase of La Senza several years ago. The firm introduced its B&BW brand into Canada in 2008 (1"The Rose Sheet" July 14, 2008)

You may also be interested in...



Bath & Body Works Makes Global Debut With Six Canadian Stores

Inspired by growing brand awareness around the world, beauty retailer Bath & Body Works is expanding outside of the U.S. with the opening of six stores in Canada this fall, Limited Brands announced July 10

Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages

The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.

Dr Reddy’s Knocked Back On Rituximab In US

Dr Reddy’s has received a complete response letter from the US FDA, knocking back its proposed rituximab biosimilar rival to Rituxan.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS016870

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel